These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20857490)

  • 1. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.
    Hu J; Nakhla H; Friedman E
    Int J Cancer; 2011 Jul; 129(2):307-18. PubMed ID: 20857490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirk regulates the exit of colon cancer cells from quiescence.
    Jin K; Ewton DZ; Park S; Hu J; Friedman E
    J Biol Chem; 2009 Aug; 284(34):22916-25. PubMed ID: 19542220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirk/dyrk1B Kinase in Ovarian Cancer.
    Friedman E
    Int J Mol Sci; 2013 Mar; 14(3):5560-75. PubMed ID: 23528858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of alterations of Rb2/p130 tumor suppressor in all-trans-retinoic acid resistant SK-OV3 ovarian carcinoma cells.
    Fields AL; Soprano DR; Soprano KJ
    J Cell Physiol; 2008 Oct; 217(1):77-85. PubMed ID: 18446820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirk kinase inhibition targets ovarian cancer ascites.
    Deng X; Hu J; Cunningham MJ; Friedman E
    Genes Cancer; 2014 May; 5(5-6):201-11. PubMed ID: 25061503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
    Soprano KJ; Purev E; Vuocolo S; Soprano DR
    Oncogene; 2006 Aug; 25(38):5315-25. PubMed ID: 16936753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.
    Gao J; Zhao Y; Lv Y; Chen Y; Wei B; Tian J; Yang Z; Kong F; Pang J; Liu J; Shi H
    Cancer Cell Int; 2013 Jan; 13(1):2. PubMed ID: 23311607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PP2A interaction with Rb2/p130 mediates translocation of Rb2/p130 into the nucleus in all-trans retinoic acid-treated ovarian carcinoma cells.
    Purev E; Soprano DR; Soprano KJ
    J Cell Physiol; 2011 Apr; 226(4):1027-34. PubMed ID: 20857408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.
    Hu J; Friedman E
    Genes Cancer; 2010 Aug; 1(8):803-811. PubMed ID: 21113238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.
    Masuda T; Itoh K; Higashitsuji H; Higashitsuji H; Nakazawa N; Sakurai T; Liu Y; Tokuchi H; Fujita T; Zhao Y; Nishiyama H; Tanaka T; Fukumoto M; Ikawa M; Okabe M; Fujita J
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10885-90. PubMed ID: 22711815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of PP2A catalytic subunit with Rb2/p130 is required for all-trans retinoic acid suppression of ovarian carcinoma cell growth.
    Purev E; Giordano A; Soprano DR; Soprano KJ
    J Cell Physiol; 2006 Feb; 206(2):495-502. PubMed ID: 16206244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K; Park S; Ewton DZ; Friedman E
    Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirk/Dyrk1B in cancer.
    Friedman E
    J Cell Biochem; 2007 Oct; 102(2):274-9. PubMed ID: 17583556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid turnover of cell-cycle regulators found in Mirk/dyrk1B transfectants.
    Ewton DZ; Lee K; Deng X; Lim S; Friedman E
    Int J Cancer; 2003 Jan; 103(1):21-8. PubMed ID: 12455049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.